阿托伐他汀钙对急性冠状动脉综合征患者PCI术后心肌微循环及内皮细胞微粒和C反应蛋白的影响(1)
[摘要] 目的 探討阿托伐他汀钙对急性冠状动脉综合征(ACS)患者经皮冠状动脉介入(PCI)术后心肌微循环及内皮细胞微粒(EMPs)和C反应蛋白(CRP)的影响。 方法 选择2014年1月～2016年11月四川省阆中市人民医院心内科收治的128例ACS患者为研究对象，按照随机数字表法将其分为对照组和观察组，每组各64例。其中，观察组患者在PCI术前12 h与术前2 h分别给予40 mg阿托伐他汀钙，对照组患者给予等量安慰剂。两组患者其余治疗过程保持一致。采用冠状动脉造影比较两组患者术后7 d的TIMI血流分级；同时比较两组患者治疗前后不同时间点静脉血中EMPs、CRP水平。 结果 观察组患者治疗后病变远端血流状况显著好于对照组(P < 0.05)。重复测量方差分析结果显示，两组患者治疗期间CPR、EMPs水平组间比较、不同时间点比较及组别与时间的交互作用差异均有统计学意义(P < 0.05)。两组术前EMPs、CRP水平比较，差异无统计学意义(P > 0.05)。与治疗前比较，两组患者术后1 d EMPs、CRP水平均明显升高，术后14 d均明显下降(P < 0.05)。观察组术后1、14 d EMPs、CRP水平均明显低于对照组同期，差异有统计学意义(P < 0.05)。 结论 阿托伐他汀钙可以有效改善ACS患者PCI术后心肌微循环，降低患者术后EMPs、CRP水平，保护内皮细胞，值得临床推广。
[关键词] 阿托伐他汀钙；急性冠状动脉综合征；经皮冠状动脉介入术；内皮细胞微粒
[中图分类号] R541.4 [文献标识码] A [文章编号] 1673-7210(2019)04(b)-0054-04
Effects of Atorvastatin Calcium on myocardial microcirculation， endothelial microparticles and C-reactive protein in patients with acute coronary syndrome after PCI
PU Yang YANG Jun
Department of Cardiology， Langzhong People′s Hospital， Sichuan Province， Langzhong 637400， China
[Abstract] Objective To investigate the effects of Atorvastatin Calcium on myocardial microcirculation， endothelial microparticles (EMPs) and C-reactive protein (CRP) in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods A total of 128 patients with ACS admitted to the Department of Cardiology， Langzhong People′s Hospital of Sichuan Province from January 2014 to November 2016 were selected as the research objects. They were divided into control group and observation group according to random number table method， 64 cases in each group. Among them， patients in the observation group were given 40 mg Atorvastatin Calcium 12 and 2 hours before PCI respectively， while patients in the control group were given the same amount of placebo. The other treatment processes of the two groups were consistent. TIMI blood flow classification at 7 days after operation was compared by coronary angiography， and the levels of EMPs and ACS in venous blood at different time points before and after treatment were compared between the two groups. Results The blood flow of the distal part of the observation group was significantly better than that of the control group (P < 0.05). The results of repeated measurement variance analysis showed that there were significant differences in CPR and EMPs levels between the two groups during treatment， at different time points， and the interaction between groups and time (P < 0.05). There was no significant difference in EMPs and CRP levels between the two groups before operation (P > 0.05). Compared with before operation， the levels of EMPs and CRP in the two groups were significantly increased at 1 day after operation， and decreased significantly at 14 days after treatment (P < 0.05). The levels of EMPs and CRP in the observation group at 1 and 14 days after operation were significantly lower than those in the control group， and the differences were statistically significant (P < 0.05). Conclusion Atorvastatin Calcium can effectively improve myocardial microcirculation， reduce EMPs and CRP levels and protect endothelial cells in ACS patients after PCI， which is worthy of clinical promotion., http://www.100md.com(蒲阳 杨军)
[关键词] 阿托伐他汀钙；急性冠状动脉综合征；经皮冠状动脉介入术；内皮细胞微粒
[中图分类号] R541.4 [文献标识码] A [文章编号] 1673-7210(2019)04(b)-0054-04
Effects of Atorvastatin Calcium on myocardial microcirculation， endothelial microparticles and C-reactive protein in patients with acute coronary syndrome after PCI
PU Yang YANG Jun
Department of Cardiology， Langzhong People′s Hospital， Sichuan Province， Langzhong 637400， China
[Abstract] Objective To investigate the effects of Atorvastatin Calcium on myocardial microcirculation， endothelial microparticles (EMPs) and C-reactive protein (CRP) in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods A total of 128 patients with ACS admitted to the Department of Cardiology， Langzhong People′s Hospital of Sichuan Province from January 2014 to November 2016 were selected as the research objects. They were divided into control group and observation group according to random number table method， 64 cases in each group. Among them， patients in the observation group were given 40 mg Atorvastatin Calcium 12 and 2 hours before PCI respectively， while patients in the control group were given the same amount of placebo. The other treatment processes of the two groups were consistent. TIMI blood flow classification at 7 days after operation was compared by coronary angiography， and the levels of EMPs and ACS in venous blood at different time points before and after treatment were compared between the two groups. Results The blood flow of the distal part of the observation group was significantly better than that of the control group (P < 0.05). The results of repeated measurement variance analysis showed that there were significant differences in CPR and EMPs levels between the two groups during treatment， at different time points， and the interaction between groups and time (P < 0.05). There was no significant difference in EMPs and CRP levels between the two groups before operation (P > 0.05). Compared with before operation， the levels of EMPs and CRP in the two groups were significantly increased at 1 day after operation， and decreased significantly at 14 days after treatment (P < 0.05). The levels of EMPs and CRP in the observation group at 1 and 14 days after operation were significantly lower than those in the control group， and the differences were statistically significant (P < 0.05). Conclusion Atorvastatin Calcium can effectively improve myocardial microcirculation， reduce EMPs and CRP levels and protect endothelial cells in ACS patients after PCI， which is worthy of clinical promotion., http://www.100md.com(蒲阳 杨军)